◆　Cystistat is Bioniche’s proprietary sodium hyaluronate product. China Medical System Holdings Ltd (CMS) has signed an exclusive agency and distribution agreement with Bioniche Teoranta to distribute Cystistat in China since March 2008.

　◆　Cystistat, sodium hyaluronate (hyaluronic acid), is for the temporary replacement of the glycosaminoglycan (GAG) layer in the bladder. There is evidence that the GAG layer of the bladder is deficient in conditions known as cystitis, a syndrome of acute or chronic origin. This deficiency contributes to the clinical symptoms in diseases such as interstitial cystitis (IC), as well as cystitis caused by infections, trauma, urolithiasis, urinary retention, neoplasia and radiation induced cystitis. Treatment with Cystistat has been shown to alleviate clinical symptoms in patients with several of these conditions. Cystistat is registered and marketed as a medical device in Canada and Europe. Cystistat received registration approval as a Medical Device from State Food and Drug Administration of China in 1999.

　◆　CMS is confident that the sales of Cystistat will contribute to CMS growing profitability.